Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Taysha Gene Therapies (TSHA) Accumulated Depreciation & Amortization (2022 - 2025)

Taysha Gene Therapies' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $4.1 million for Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization rose 12.95% year-over-year to $4.1 million; the TTM value through Jun 2025 reached $4.1 million, up 12.95%, while the annual FY2024 figure was $3.6 million, 20.31% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2025 was $4.1 million at Taysha Gene Therapies, up from $3.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $4.1 million in Q2 2025 and bottomed at $1.3 million in Q3 2022.
  • The 4-year median for Accumulated Depreciation & Amortization is $2.8 million (2023), against an average of $2.7 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 105.2% in 2023 before it increased 12.95% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $1.6 million in 2022, then skyrocketed by 81.43% to $3.0 million in 2023, then rose by 20.31% to $3.6 million in 2024, then rose by 14.37% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Accumulated Depreciation & Amortization are $4.1 million (Q2 2025), $3.6 million (Q4 2024), and $3.6 million (Q2 2024).